Skip to main content
. 2020 May 13;109(10):1197–1222. doi: 10.1007/s00392-020-01636-7

Table 2.

Target structure and half-life of immune checkpoint inhibitors, modified according to [20]

Target structure Half-life
Ipilimumab CTLA-4 15 days
Atezolizumab PD-L1 27 days
Avelumab 6.1 days
Durvalumab 21 days
Nivolumab PD-1 25 days
Pembrolizumab 27.3 days
Cemiplimab 19 days

CTLA-4 cytotoxic t-lymphocyte-associated-protein 4, PD-L1 programmed cell death-1 ligand 1, PD-1 programmed cell death-1